SCHEMBL21797184

SCHEMBL21797184

CC(C)(C)n1cnc(-c2ccc(F)cc2)c1-c1ccnc(N)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 14/20 0.67
MAPK13 O15264 4/20 0.61
MAPK12 P53778 4/20 0.61
MAPK11 Q15759 4/20 0.61
CSNK1E P49674 3/20 0.58
CSNK1D P48730 2/20 0.58
EGFR P00533 1/20 0.58
KCNH2 Q12809 1/20 0.58
RIPK2 O43353 1/20 0.56
DYRK3 O43781 1/20 0.56
PRKD3 O94806 1/20 0.56
MAP4K4 O95819 1/20 0.56
PRKCG P05129 1/20 0.56
LCK P06239 1/20 0.56
LYN P07948 1/20 0.56
RET P07949 1/20 0.56
PIM1 P11309 1/20 0.56
PRKACA P17612 1/20 0.56
MAPK1 P28482 1/20 0.56
FLT4 P35916 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20550774 0.83 MAPK14 (0.71) MAPK14MAPK13MAPK12MAPK11CSNK1E
SCHEMBL23795663 0.83 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11CSNK1E
SCHEMBL29842089 0.83 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11CSNK1E
SCHEMBL4925073 0.81 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11CSNK1E
SCHEMBL21797182 0.81 MAPK14 (0.53) MAPK14MAPK13MAPK12MAPK11
SCHEMBL20550895 0.80 MAPK14 (0.71) MAPK14MAPK13MAPK12MAPK11CSNK1E
SCHEMBL4916571 0.80 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11CSNK1E
SCHEMBL28400055 0.80 MAPK14 (0.52) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL4916578 0.78 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11CSNK1E
SCHEMBL20550753 0.78 MAPK14 (0.91) MAPK14MAPK13MAPK12MAPK11CSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3619204-B1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES TIANLI BIOTECH PTY LTD (AU) 2025-10-01 EP disclosed
US-20220380343-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES TIANLI BIOTECH PTY LTD (AU) 2022-12-01 US disclosed
US-20200079757-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES THE UNIVERSITY OF MELBOURNE (AU) 2020-03-12 US disclosed
CN-110753688-A Compounds for the treatment of respiratory diseases 墨尔本大学 2020-02-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380343-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES LTC4S, LTB4R2, LTB4R MAPK14 4326/4885MAPK13 3615/4885MAPK12 3309/4885
US-20200079757-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES LTC4S, LTB4R2, LTB4R MAPK14 4326/4885MAPK13 3615/4885MAPK12 3309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.